NEELS GUIDO J 4

What Happened
Guido J. Neels, a director of Bioventus, had 32,282 restricted stock units (RSUs) that vested and were converted/exercised on June 2, 2026 (reported as derivative exercise/conversion, code M). The filing also shows a simultaneous disposal of 32,282 derivative units on June 2 (reported at $0). On June 3, 2026 he was granted 25,146 RSUs (reported as an award, code A). All reported exercise/grant prices are $0 and the Form 4 shows no cash values for these entries.

Key Details

• Transaction dates and types: 6/2/2026 — exercise/conversion of 32,282 RSUs (M) and a reported disposal of 32,282 (derivative) at $0; 6/3/2026 — grant/award of 25,146 RSUs (A) at $0.
• Prices/values: all entries report $0 exercise/grant price; the filing does not list cash proceeds.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU equals a contingent right to one share; F2 — the RSUs vested on June 2, 2026; F3 — the new RSUs vest on the earlier of the issuer’s first annual meeting after grant or the first anniversary of grant, subject to continued board service.
• Filing timeliness: Reported on 6/4/2026 for transactions on 6/2–6/3/2026; this appears to be filed within the usual SEC Form 4 reporting window.

Context: These transactions involve RSU vesting/conversion and a follow-on RSU grant — common board compensation actions. An exercise/conversion at $0 indicates no cash strike price for converting RSUs to shares; the filing does not state market proceeds or whether any shares were sold into the market. Awards and vesting reflect compensation and not necessarily an indication of the director’s view of the company’s stock.